Seryx

Seryx was a pharmacogenetics and medical information technology company that specialized in interpreting genetic data to optimize drug therapy. Its flagship service, Signature Genetics, utilized a proprietary knowledge base and algorithms to analyze a patient's genotype—specifically variations in cytochrome P450 enzymes—to predict drug response and the risk of adverse reactions. The company's technology, including the Drug Regimen Optimizer, provided physicians with actionable reports for personalized dosing and drug selection across various therapeutic areas. Seryx established a significant partnership with LabCorp to offer its interpretive services, though it later faced regulatory challenges from the FDA regarding the classification of its software as a medical device.